Skip to main content

Dri Healthcare Trust USD(DHT-U-T)
TSX

Today's Change
Real-Time Last Update
Day Low12.38
Day High12.53
Open:12.40
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Newswire.ca
DRI Healthcare Trust Announces Participation in Upcoming Investor Conferences
Newswire.ca
DRI Healthcare Trust to Host Fourth Quarter and Full Year 2023 Earnings Call and Webcast on February 29, 2024
Newswire.ca
DRI Healthcare Trust Declares Special Distributions
Newswire.ca
DRI Healthcare Trust Announces Upsized US$500 Million Credit Facilities
Newswire.ca
DRI Healthcare Trust to Host Third Quarter Earnings Call and Webcast on November 14, 2023
GlobeNewswire
DRI Healthcare Trust Announces C$90 Million Bought Deal Public Offering of Units
GlobeNewswire
DRI Healthcare Trust Announces C$85 Million Bought Deal Public Offering of Units
Newswire.ca
DRI Healthcare Trust to Host Fourth Quarter and Full Year 2022 Earnings Call and Webcast on March 2, 2023
The Globe and Mail
National Bank reveals its 2023 ‘Dividend All-Stars’
The Globe and Mail
IA Capital Markets reveals its 2023 stock picks for an ‘extremely dynamic environment’
Newswire.ca
DRI Healthcare Trust Declares Unit Distribution and Provides Update on Normal Course Issuer Bid
Newswire.ca
DRI Healthcare Trust Announces Appointment of Poonam Puri to Board of Trustees
Newswire.ca
DRI Healthcare Trust to Host Third Quarter Earnings Call and Webcast on November 8, 2022
Newswire.ca
DRI Healthcare Trust Announces Participation in Upcoming Investor Conferences

Profile

DRI Healthcare Trust is engaged in pharmaceutical royalty monetization by providing capital to inventors, academic institutions, and biopharma companies. Trust was formed to provide Unitholders with differential exposure to the pharmaceutical and biotechnology industries through ownership and acquisitions of pharmaceutical royalties. In return for providing capital to biopharmaceutical innovators, the company is building a diversified portfolio of interests in medicines that have a demonstrable positive impact on the world. The Trust has concluded that it operates as one segment, primarily focused on acquiring royalty assets. Geographically the trust generates major revenue from the United States. The trust also generates Income from markets such as Japan, and the European Union.